- Home
- EYPT vs ATAI Comparison
EYPT vs ATAI Comparison
Compare EYPT & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EYPT
- ATAI
- Stock Information
- Founded
- EYPT 1987
- ATAI 2018
- Country
- EYPT United States
- ATAI Germany
- Employees
- EYPT N/A
- ATAI N/A
- Industry
- EYPT Biotechnology: Laboratory Analytical Instruments
- ATAI Biotechnology: Pharmaceutical Preparations
- Sector
- EYPT Industrials
- ATAI Health Care
- Exchange
- EYPT Nasdaq
- ATAI Nasdaq
- Market Cap
- EYPT 484.4M
- ATAI 444.7M
- IPO Year
- EYPT 2005
- ATAI 2021
- Fundamental
- Price
- EYPT $10.37
- ATAI $2.25
- Analyst Decision
- EYPT Strong Buy
- ATAI Strong Buy
- Analyst Count
- EYPT 8
- ATAI 3
- Target Price
- EYPT $24.75
- ATAI $10.50
- AVG Volume (30 Days)
- EYPT 817.0K
- ATAI 2.7M
- Earning Date
- EYPT 08-06-2025
- ATAI 08-12-2025
- Dividend Yield
- EYPT N/A
- ATAI N/A
- EPS Growth
- EYPT N/A
- ATAI N/A
- EPS
- EYPT N/A
- ATAI N/A
- Revenue
- EYPT $56,042,000.00
- ATAI $1,863,000.00
- Revenue This Year
- EYPT N/A
- ATAI $554.22
- Revenue Next Year
- EYPT N/A
- ATAI N/A
- P/E Ratio
- EYPT N/A
- ATAI N/A
- Revenue Growth
- EYPT 12.04
- ATAI 572.56
- 52 Week Low
- EYPT $3.91
- ATAI $1.03
- 52 Week High
- EYPT $13.99
- ATAI $2.64
- Technical
- Relative Strength Index (RSI)
- EYPT 72.76
- ATAI 54.36
- Support Level
- EYPT $7.94
- ATAI $2.06
- Resistance Level
- EYPT $10.77
- ATAI $2.51
- Average True Range (ATR)
- EYPT 0.74
- ATAI 0.18
- MACD
- EYPT 0.10
- ATAI -0.04
- Stochastic Oscillator
- EYPT 85.87
- ATAI 45.45
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.
About ATAI ATAI Life Sciences N.V.
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company on a mission to develop effective mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 (buccal film DMT) for treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder. It is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for TRD.